1365-2141/asset/olbannerleft.gif?v=1&s=2237887a0dba115836e329b1c5824f93749b814b)
1365-2141/asset/olbannerright.gif?v=1&s=01b5795d608a5571b530fcd8eb300f01b48de3b2)
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation
Article first published online: 24 DEC 2001
DOI: 10.1046/j.1365-2141.2000.01847.x
1365-2141/asset/cover.gif?v=1&s=340532f3ee73ba9171e38abd4d7f6a926d117661 "British Journal of Haematology")
Additional Information
How to Cite
Silvestri, Ermacora, Sperotto, Patriarca, Zaja, Damiani, Fanin and Baccarani (2000), Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. British Journal of Haematology, 108: 394–396. doi: 10.1046/j.1365-2141.2000.01847.x
Publication History
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
- Abstract
- Article
- References
- Cited By
Keywords:
- Lamivudine;
- hepatitis B reactivation;
- chemotherapy;
- lymphoma
Reactivation of hepatitis B virus in patients receiving chemotherapy for non-Hodgkin's lymphoma (NHL) may give rise to hepatitis, hepatic failure and death, and prevent further chemotherapy. We report four patients with NHL in whom hepatitis flare-up was observed after two (three patients) and six (one patient) cycles of chemotherapy. After spontaneous recovery, they were treated with Lamivudine (100 mg/day), which enabled completion of chemotherapy without further hepatitis B reactivation. In one patient, high-dose chemotherapy and autologous stem cell transplantation was also performed. These data suggest a possible role for Lamivudine in preventing hepatitis B reactivation during chemotherapy administration to chronic carriers of the hepatitis B virus. Moreover, it enabled the completion of both standard and high-dose chemotherapy in patients with previous hepatitis B reactivation.